GNPX - Genprex, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
1.8142
+0.0141 (+0.78%)
As of 9:52AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close1.8001
Open1.8142
Bid1.7900 x 2900
Ask1.8900 x 1300
Day's Range1.8142 - 1.8142
52 Week Range0.9500 - 19.4500
Volume491
Avg. Volume47,130
Market Cap27.345M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.7470
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.25
Trade prices are not sourced from all markets
  • GlobeNewswire3 days ago

    Genprex Inc. Discusses Plans to Expand Clinical Trials in Fight Against Cancer in Exclusive Audio Interview with NetworkNewsWire

    NEW YORK, March 19, 2019 (GLOBE NEWSWIRE) -- via NetworkWire – NetworkNewsAudio (NNA), a NetworkNewsWire (NNW) Solution that delivers clients unparalleled visibility, recognition and brand awareness in the investment community, today announces the online availability of its interview with Genprex Inc., a clinical stage gene therapy company developing a new approach to treating cancer. NNW’s Stuart Smith introduces Genprex CEO and Chairman Rodney Varner, JD, for a compelling discussion on the company’s initial product candidate, Oncoprex(TM), an immunogene therapy for non-small cell lung cancer (NSCLC). The American Cancer Society reports that NSCLC is the most common type of lung cancer, accounting for about 85 percent of all lung cancer.

  • Newsfile7 days ago

    NetworkNewsAudio Announces Audio Press Release (APR) on Genprex Inc.'s Transformative Work in Gene Therapy

    New York, New York--(Newsfile Corp. - March 15, 2019) - NetworkNewsAudio announces the Audio Press Release (APR) titled "Making Profits, Saving Lives with Gene Therapy," featuring Genprex Inc. (NASD: GNPX).To hear the NetworkNewsAudio version, visit: http://nnw.fm/bw1cXTo read the full editorial, visit: http://nnw.fm/Y0ZqHThis evidence of the faith of the markets has helped boost stock values for a range of gene therapy companies, with some seeing triple digit growth. But these companies don't need to be the ...

  • GlobeNewswire7 days ago

    NetworkNewsAudio Announces Audio Press Release (APR) on Genprex Inc.’s Innovative Approach to Gene Therapy

    NEW YORK, March 15, 2019 (GLOBE NEWSWIRE) -- via NetworkWire – NetworkNewsAudio announces the Audio Press Release (APR) titled “Making Profits, Saving Lives with Gene Therapy,” featuring Genprex Inc. (GNPX). Delivery systems for the genes are as important as the genes themselves. Carriers called vectors deliver the genetic material into the cells.

  • Business Wire8 days ago

    Genprex to Present at ARM Cell & Gene Therapy Investor Day in New York City

    Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, today announced it will be presenting at the upcoming Cell & Gene Therapy Investor Day presented by the Alliance for Regenerative Medicine in New York City on March 21, 2019.

  • GlobeNewswire8 days ago

    NetworkNewsWire Announces Publication on Gene Therapy’s Promise for Improving Patient Treatments and Market Profitability

    NEW YORK, March 14, 2019 -- via NetworkWire — NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial.

  • GuruFocus.com9 days ago

    5 Biotech Stocks to Keep an Eye on in 2019

    The biotech sector is an interesting one to follow. Warning! GuruFocus has detected 2 Warning Sign with CELG. There has been quite a bit of chatter recently surrounding the potential acquisition of the company by Bristol-Myers Squibb (BMY).

  • Business Wire23 days ago

    Genprex Strengthens Senior Team and Continues to Advance Operations

    Genprex, Inc. (NASDAQ: GNPX) a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform announced that it is continuing to grow its senior team with the hiring of Eric Chapdelaine, Senior Director of Pharmaceutical Sciences and Manufacturing, and Kalyn Dabbs, Senior Manager of Communications and Marketing, effective immediately.

  • Genprex Appoints John N. Bonfiglio, PhD, to Board of Directors
    Business Wirelast month

    Genprex Appoints John N. Bonfiglio, PhD, to Board of Directors

    Genprex, Inc. (NASDAQ: GNPX) a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today the appointment of John N. Bonfiglio, PhD, to the company’s Board of Directors. In recent years, Dr. Bonfiglio served as President and CEO of Oragenics, Inc. and most recently as President and COO of TapImmune, Inc., where he helped lay the groundwork for a successful merger with Marker Therapeutics, Inc. in October 2018 by up-listing TapImmune to Nasdaq and starting a robust clinical program in breast and ovarian cancers.

  • Business Wire2 months ago

    Genprex to Present at NobleConXV in Fort Lauderdale, Florida

    Genprex, Inc. (GNPX), a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, today announced that its President and Chief Operating Officer, Julien Pham, MD, MPH, will deliver a presentation about the company’s unique, leading-edge gene therapies and will also participate in a discussion panel on the topic of “Novel Therapies at the Cutting Edge of Cancer Research” at NobleConXV - Noble Capital Markets’ Fifteenth Annual Investor Conference at the W Hotel in Fort Lauderdale, Florida.

  • Business Wire3 months ago

    Genprex to Present at Biotech Showcase™ 2019 in San Francisco

    Genprex, Inc. (GNPX), a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, today announced that it will present at Biotech Showcase™ 2019, to be held January 7–9, during the most important week in healthcare finance at the Hilton San Francisco Union Square. Genprex is pioneering a new approach to treating cancer–based upon a novel proprietary technology platform–that includes the company’s initial product candidate, Oncoprex™ immunogene therapy.

  • Are Insiders Buying Genprex, Inc. (NASDAQ:GNPX) Stock?
    Simply Wall St.3 months ago

    Are Insiders Buying Genprex, Inc. (NASDAQ:GNPX) Stock?

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On the other hand, we'd be remiss not to mention Read More...

  • Business Wire3 months ago

    Genprex to Launch Investors Website and Increase Emphasis on Investor Relations in 2019

    Genprex, Inc. (NASDAQ: GNPX) a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today that it will be increasing its investor relations efforts in 2019, spearheaded by the launch of an innovative corporate website with more robust investor resources, including the company’s presentations, stock charts and integrated quotes, SEC filings, news, media coverage, and tailored email newsletters, among other advanced communication tools. As part of today’s announcement, investors already have the ability to receive all news regarding Genprex straight to their inbox by signing up for the company’s communication list at https://www.genprex.com/investors/email-alerts/.

  • Business Wire4 months ago

    Genprex to Present at the 11th Annual LD Micro Main Event

    Presentation Wed., Dec. 5, 2018, at 10:30 a.m. PST

  • Business Wire4 months ago

    Genprex Provides Clinical and Corporate Update for Third Quarter 2018

    Genprex, Inc. (GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, today announced a clinical and corporate update, and the filing of quarterly results for the third quarter ended September 30, 2018 on Form 10-Q with the Securities and Exchange Commission. Rodney Varner, Chairman and CEO, remarked, “Over the past quarter, we have taken steps to advance our clinical development activities.

  • Business Wire5 months ago

    Genprex Appoints Jan Stevens, RN, as Vice President of Clinical Operations

    Genprex, Inc. (GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today the appointment of Jan Stevens, RN, as the Company’s Vice President of Clinical Operations. In this role, Ms. Stevens joins the Cambridge office to contribute in supporting various clinical development programs for the Company’s immunogene therapy, Oncoprex™, which is currently being evaluated in clinical and preclinical studies at MD Anderson Cancer Center for the treatment of non-small cell lung cancer (NSCLC).

  • Business Wire6 months ago

    Genprex to Present at Upcoming Investor and Industry Conferences

    Genprex, Inc. , a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today

  • Business Wire6 months ago

    Genprex™ Taps Aldevron to Supply TUSC2 Plasmid DNA for Oncoprex Clinical Development Program

    Genprex, Inc. (GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, has signed an agreement with Aldevron, a leading contract manufacturing organization, to supply TUSC2 (Tumor Suppressor Candidate2) plasmid DNA for use in Genprex’s clinical development program evaluating its immunogene therapy Oncoprex™ for the treatment of non-small cell lung cancer.

  • Business Wire7 months ago

    Genprex to Present at Upcoming Investor Conferences

    Genprex, Inc. , a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today

  • Business Wire7 months ago

    Genprex Provides Clinical and Corporate Update for Second Quarter 2018

    Genprex, Inc. (GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, today announced a clinical and corporate update, and the filing of quarterly results for the second quarter ended June 30, 2018 on Form 10-Q with the Securities and Exchange Commission. Rodney Varner, Chairman and CEO, remarked, “We have made significant progress in recent months to advance the development of Oncoprex™ for treatment of non-small cell lung cancer (NSCLC), including engaging collaborators with expertise and other resources necessary for important pre-clinical and clinical services.

  • Business Wire8 months ago

    Genprex Updates Agreement with University of Texas MD Anderson Cancer Center to Resume Patient Enrollment in Phase I/II Study Evaluating Oncoprex/Erlotinib Combination Therapy in Non-Small Cell Lung Cancer

    Genprex, Inc. (GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, today announced that it has amended its agreement with The University of Texas MD Anderson Cancer Center to resume patient enrollment in its Phase I/II clinical trial evaluating the combination of the company’s investigational drug Oncoprex™ and erlotinib (Tarceva®) for the treatment of Stage IV non-small cell lung cancer (NSCLC). Oncoprex is a TUSC2 gene encapsulated in a positively charged nanovesicle made from lipid molecules and injected intravenously, which can specifically target cancer cells and insert wild-type TUSC2 into cellular DNA, effectively increasing expression of the TUSC2 protein and promoting tumor cell death.

  • Business Wire8 months ago

    Genprex Enters Agreement with the University of Texas MD Anderson Cancer Center to Study Oncoprex in Combination with Immunotherapies

    Genprex, Inc. (GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, has entered a Sponsored Research Agreement (“Agreement”) with The University of Texas MD Anderson Cancer Center under which Genprex will sponsor a pre-clinical study, entitled “A Novel Therapeutic Approach for the Treatment of Cancer Using a Combination of the Multifactorial Tumor Suppressor Gene TUSC2 and Immunotherapy,” to be conducted under the direction of Jack A. Roth, MD, FACS. TUSC2 is the active agent in Genprex’s investigational drug candidate Oncoprex™.

  • Genprex To Present At The Singular Research Summer Solstice 2018 Conference
    PR Newswire8 months ago

    Genprex To Present At The Singular Research Summer Solstice 2018 Conference

    NEW YORK , July 18, 2018 /PRNewswire/ -- Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, ...

  • Genprex Selects 4Clinics To Provide Clinical And Regulatory Support For Oncoprex Development Program
    PR Newswire9 months ago

    Genprex Selects 4Clinics To Provide Clinical And Regulatory Support For Oncoprex Development Program

    AUSTIN, Texas AND CAMBRIDGE, Mass., June 26, 2018 /PRNewswire/ -- Genprex, Inc. (GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, has selected 4Clinics Group Sprl to provide support for the clinical development of the Company's lead drug candidate, Oncoprex™, for the treatment of non-small cell lung cancer (NSCLC). "This is an important step forward for Genprex as we expand the scope of the Oncoprex clinical development program to build on the encouraging data we've compiled to date," said Julien Pham, MD, MPH, President and Chief Operating Officer of Genprex. 4Clinics is a global contract research organization that provides comprehensive clinical expertise to clients across data management, biostatistics, statistical programming, scientific writing, regulatory affairs and clinical operations services for clinical, observational and epidemiological studies.

  • Genprex Engages WIRB-Copernicus Group, Inc. To Provide Clinical Trial Services To Support Oncoprex Clinical Trial Program
    PR Newswire10 months ago

    Genprex Engages WIRB-Copernicus Group, Inc. To Provide Clinical Trial Services To Support Oncoprex Clinical Trial Program

    AUSTIN, Texas, May 31, 2018 /PRNewswire/ -- Genprex, Inc. (GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today that it entered into a Master Services Agreement with WIRB-Copernicus Group, Inc. ("WCG"), through which WCG will serve as the Institutional Review Board (IRB) and Institutional Biosafety Committee (IBC) of record for new clinical trial sites that Genprex anticipates adding to participate in its  Phase I/II clinical trial of lead product candidate, OncoprexTM, in combination with erlotinib (Tarceva®) in non-small cell lung cancer.